Undertreatment or Overtreatment With Statins: Where Are We?

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Lipid-lowering therapies, primarily statins, are essential for managing dyslipidemias.
• Newer agents like ezetimibe and PCSK9 inhibitors offer additional LDL-C reduction options.
• Evolving clinical guidelines emphasize lower LDL-C targets, promoting a 'lower is better' approach.

Purpose of the Study:

• To review the efficacy of lipid-lowering drugs in reducing cardiovascular events.
• To discuss the pleiotropic effects of statins beyond lipid reduction.
• To analyze real-world data on undertreatment and overtreatment of lipid-lowering therapies and evolving LDL-C targets.

Main Methods:

• Narrative review of existing clinical trial evidence and observational studies.
• Analysis of changes in clinical guidelines for dyslipidemia management over time.
• Examination of patient engagement and shared decision-making in lipid-lowering therapy selection.

Main Results:

• Lipid-lowering drugs significantly reduce cardiovascular events.
• Statins exhibit beneficial pleiotropic effects.
• Real-world LDL-C control remains suboptimal, highlighting gaps in guideline adherence.

Conclusions:

• Optimizing LDL-C management requires enhanced adherence to current guidelines.
• Shared decision-making and patient engagement are critical for effective lipid-lowering therapy.
• Continuous re-evaluation of therapeutic goals is necessary in light of new evidence.